CytomX Therapeutics Inc CTMX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-10-08 |
| Shares Out. | 217,700,000 |
| Website | cytomx.com/ ↗ |
| Phone | 16505153185 |
| Employees | 69 |
| Revenue | $10.3M |
| Gross Profit | $10.3M |
| Net Income | -$18.2M |
| Free Cash Flow | -$80.2M |
| Total Assets | $359.4M |
| Total Liabilities | $39.4M |
| Equity | $319.9M |
About CytomX Therapeutics Inc
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
CytomX Therapeutics Inc is a publicly traded company under the ticker symbol CTMX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)